ArticleERJ open research2020
Immune defects in patients with pulmonary
Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Lower airway dysbiosis in nontuberculous mycobacteria-positive bronchiectasis is associated with neutrophil extracellular trap-predominant severe phenotypes.American journal of respiratory and critical care medicine · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- The Crosstalk BetweenCells · 2025Review
- Serum cytokine analysis in cavitary and non-cavitary pulmonary Mycobacterium avium complex disease: a cross-sectional study.BMC infectious diseases · 2025Article
- Discovery of Biofilm-Inhibiting Compounds to Enhance Antibiotic Effectiveness AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Prevalence of Chronic Obstructive Pulmonary Disease in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Systemic Review and Meta-Analysis.Journal of personalized medicine · 2024Review
- An optimized cyclophosphamide-treated mouse model ofAntimicrobial agents and chemotherapy · 2024Article
- Growing from common ground: nontuberculous mycobacteria and bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Article
- MarR-Dependent Transcriptional Regulation ofAntimicrobial agents and chemotherapy · 2023Article
- Amikacin Liposomal Inhalation Suspension in the Treatment ofOpen forum infectious diseases · 2022Article
- RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2022Article
- Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients.Clinics and practice · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.